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doi:10.1016/j.jtcvs.2005.11.044bjective: We sought to examine the distribution and prognostic implications of
odal metastasis in patients undergoing extrapleural pneumonectomy for malignant
esothelioma in a specialist center.
ethods: We have examined the lymphadenectomy specimens from 92 consecutive
ases of malignant mesothelioma undergoing extrapleural pneumonectomy from
eptember 1999 through February 2005 inclusive. Nodal stations (Naruke) were
ssigned to all nodes, and patients were staged according to the current International
nion Against Cancer system. The status and number of nodes in each station were
ecorded, and results were correlated with the results of preoperative mediastino-
copic findings (n  30) and survival.
esults: The nodal distribution was 48 N0, 9 N1, and 35 N2. Single and multistation
odal involvement was present in 20 and 24 cases, respectively. Among the patients
ndergoing mediastinoscopy, N2 disease after extrapleural pneumonectomy oc-
urred in 10 (33%). Skip N2 metastasis was present in 10 (42%) cases. Positive N2
odes inaccessible by mediastinoscopy were present in 17 (49%) cases. N2 metas-
asis was associated with reduced survival (P  .02), but there was no difference
etween N1 and N2 cases (P  .4). The number of positive nodes correlated with
urvival (P  .001), although the number of involved stations and their anatomic
ocation did not. There was no difference in survival between skip N2 cases and
ither other N2 or N1 cases.
onclusions: The classical anatomic location is not as important as the scatter of
odal involvement. Every effort should be made to obtain biopsy specimens from as
any stations as possible before undertaking extrapleural pneumonectomy for
alignant mesothelioma.
number of different staging systems has been used over the years for
malignant mesothelioma (MM).1 The most widely used in current practice
is the TNM staging system proposed by the International Mesothelioma
nterest Group in 1995 and subsequently adopted by the International Union Against
ancer (UICC). With regard to nodal metastasis, the same distinction between ipsilat-
ral parenchymal-hilar (N1) and mediastinal (N2) nodes is made as for non–small cell
ung cancer (NSCLC).2 Extrapleural nodal metastasis has been identified as a poor
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G
TSrognostic factor in many published series. Sugarbaker and
olleagues3 noted that metastasis to extrapleural lymph nodes
onfers a poor prognosis, being an independent prognostic
actor that they incorporated into the Brigham staging system.
MM arises first in the parietal pleura before nodules on
he visceral surface appear.4 This is reflected in the UICC
NM staging system, within which T1a designates multiple
solated tumor nodules over the parietal pleural surface,
ith the visceral surface remaining macroscopically nor-
al.1 However, the lymph drainage from the parietal pleura
oes not flow to bronchopulmonary or hilar nodes but might
ass through those lying alongside the internal thoracic
rtery or diaphragm.
There are few data regarding the pattern of nodal spread
f MM. Skip metastases, cases in which N2 nodes are
nvolved but N1 nodes are not, have not been characterized
n MM as they have in NSCLC, where they might confer a
etter prognosis than other N2 categories.5 The implications
f lymph node drainage to nonmediastinal N2 nodes (inter-
al thoracic artery and diaphragmatic) is unclear. The aim of
his study was to validate the current nodal staging system
or MM and to examine the clinical implications of any
ariance from this classification for staging before ex-
rapleural pneumonectomy (EPP).
atients and Methods
ince August 1999, patients with early-stage MM have been
ssessed at our institution with a view to EPP. The 92 consecutive
atients entered into this study up to and including February 2005
ad MM proved at either video-assisted thoracoscopy or open
leural biopsy. The histopathologic diagnosis was confirmed with
he use of immunohistochemical techniques. All patients under-
ent contrast-enhanced computed tomographic scans. Contrast-
nhanced magnetic resonance imaging scans were performed in
atients in whom there was doubt regarding local invasion poten-
ially precluding respectability.6 Finally, we have used video-
ssisted mediastinoscopy for biopsy of lymph nodes in stations
/4L, 2/4R, and 7, regardless of their size on the computed tomo-
raphic scan, after our finding that nodal size did not correlate with
alignant involvement.7 Patients’ tumors were judged to be re-
ectable if the tumor did not show extrathoracic extension or
nvade mediastinal organs or across the diaphragm (clinical T1-3
0-1). We have not performed staging laparoscopy in this series.
Assessment of operability involved the calculation of the pre-
icted postoperative forced expiratory volume in 1 second and
ostoperative carbon monoxide transfer factor. Differential quan-
Abbreviations and Acronyms
EPP  extrapleural pneumonectomy
MM malignant mesothelioma
NSCLC non–small cell lung cancer
UICC  International Union Against Canceritative radionuclide ventilation-perfusion scanning was used in h
82 The Journal of Thoracic and Cardiovascular Surgery ● Mayorderline cases. Transthoracic echocardiography was performed
n all cases. Operability criteria included a postoperative forced
xpiratory volume in 1 second and postoperative carbon monoxide
ransfer factor of greater than 50% of predicted value and a mean
ulmonary artery pressure estimated at less than 35 mm Hg with
ood ventricular function.
Left EPP was performed through a posterolateral thoracotomy,
n the majority through the seventh intercostal space alone. Ini-
ially, right EPP was performed through a right posterolateral
horacotomy, although latterly a median sternotomy has been the
ncision of choice. En bloc excision of the lung, pleura, hemiperi-
ardium, and hemidiaphragm, followed by reconstruction of the
ericardium and diaphragm, was performed according to standard
echniques.8
Systematic lymph node dissection was performed according to
he technique described by Graham and associates9 for NSCLC.
fter fixation of the main specimen and separately sent lymph
odes in formalin, samples were selected by a pathologist and
mbedded in paraffin. Hematoxylin and eosin–stained tissue sec-
ions were analyzed by means of light microscopy to determine
ymph node involvement. In certain cases in which the possibility
f nodal disease was suggested by the presence of atypical cells,
mmunohistochemisty was used to clarify the origin of the cells,
nd lymph node stations were derived according to the Naruke
ap.2 The total number of nodes and the number involved were
oted for each station.
EPP was offered intentionally as part of a multimodality treat-
ent program, including either chemotherapy, radical radiother-
py, or both.
Video-assisted mediastinoscopy was performed in 30 patients,
ncluding 2 patients who also underwent a positron emission
omographic scan. Positron emission tomography alone was used
s mediastinal staging in a further 3 patients. EPP was carried out
n 92 patients (median age, 57 years; age range, 38-70 years; 82
ale patients). Right EPP was performed in 46 patients, and this
as by means of median sternotomy in 23 patients.
Statistical analysis was carried out with the software package
PSS for Windows, version 11 (SPSS Inc). Differences between
roups in survival from the date of diagnosis were estimated
ccording to Kaplan-Meier methods by using the log-rank test. The
ate of diagnostic biopsy was used rather than the date of surgical
ntervention to remove bias from patients who underwent neoad-
uvant chemotherapy. Patients dying in the immediate postopera-
ive period from causes not related to tumor progression were
ensored in the survival analyses. Differences in distribution of
ariables between groups were examined with the 2 test.
esults
ata are expressed as medians (ranges).
The operation time was 3.75 hours (range, 1.5-6.3 hours),
nd postoperative stay was 13 days (range, 5-184 days). There
ere 7 (7.6%) in-hospital deaths. Final pathologic stage was I,
I, III, and IV in 6, 8, 54, and 24 patients, respectively. There
ere 48 node-negative patients, 9 N1 (5 stage III and 4 stage
V) and 35 N2 (20 stage III and 15 stage IV). The final
istologic subtype was nonepithelioid in 21 cases.
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TSodal Stage
he number of nodes reported by the pathologist was 14
range, 1-48). The median number of positive nodes was 3
range, 1-15) from 2 (range, 1-5) stations. Skip metastases,
n which N2 nodes were positive but N1 nodes were nega-
ive, occurred in 14 (40%) of the 35 patients with N2 nodes.
he distribution of the 17 nodal stations positive in these 14
atients is shown in Table 1. Positive N1 nodes were found
n a total of 30 patients (9 staged N1 and 21 staged N2).
fter mediastinoscopy, false-negative N2 disease was found in
0 (33%) patients. The negative predictive value for video-
ssisted mediastinoscopy was 97% for stations 2/4L, 94% for
tations 2/4R, and 79% for station 7. Among the 35 patients
ith N2 nodes at lymph node dissection, positive nodes
naccessible to mediastinoscopy were found in 17 (49%)
atients (Table 1). In 8 patients (23% N2 positive), these
ere the only positive N2 nodes found.
onsurgical Treatment Modalities
he patients referred originated from 28 oncology centers.
ince September 2002, our referring oncologists have ad-
inistered neoadjuvant chemotherapy to 20 patients. All
atients in whom neoadjuvant chemotherapy was completed
nderwent EPP. Only 10 received adjuvant chemotherapy,
nd to date, 14 have received chemotherapy at the time of
ymptomatic disease progression. Radical trimodality ther-
py, including hemithorax irradiation, has been successfully
ompleted in 6 cases.
urvival
verall median survival for the whole cohort of patients
including the postoperative deaths) was 14.9 months. One-
ABLE 1. Anatomic distribution of the nodes sampled at
xtrapleural pneumonectomy
tation
Skip
metastases
Positive N2 nodes
in false-negative
mediastinoscopy
cases
Positive N2 nodes
inaccessible to
mediastinoscopy
o. of patients 14 10 17
o. of nodes 18 16 1
2/4L 2 1
2/4R 5 2
5 1 1
6 1
7 4 6
8 2 1 7
9 1 1 1
Internal thoracic
artery
2 2 2
Pericardial 2 3
Diaphragmatic 2 3nd 2-year survival rates were 59% and 34%, respectively. (
The Journal of Thoracicmong those surviving surgical intervention, UICC TNM
tage did not predict survival (stage I and II median survival
ot reached; stage III, 15.1 months; stage IV, 18.8 months;
  .11, Figure 1). Nodal status, expressed as N0 versus N1
ersus N2, was associated with a significant survival differ-
nce between groups (P  .02), as was combining the N0
nd N1 groups (N0 and N1, 27.9 months; N2, 14 months; P
 .02, Figure 2 ). Survival in the skip N2 metastasis group
id not differ from that in the N1 group or the other N2
roup (P  .3 and P  .6, respectively).
Significant differences in survival were apparent be-
ween those with 0 to 3 positive nodes (79 patients) com-
ared with those with greater than or equal to 4 positive
odes (13 patients, P  .001) and also those with a higher
han median proportion of positive nodes in either N1 (P 
04, Figure 3) or N2 (P  .04) stations. Among the patients
ith N2-positive disease, there was no significant survival
ifference between those positive in stations 2, 4, and 7 and
hose only positive in other stations (P  .9).
ther Prognostic Factors and Multivariate Analyses
ther factors in this series that predicted good prognosis in
nivariate analysis with the log-rank test were a hemoglobin
alue at diagnosis of greater than 14 g/dL (n  49, P 
009) and receipt of either neoadjuvant or adjuvant chemo-
herapy (n  30, P  .008). Sex, histologic subtype, per-
ormance status, and T stage were not significant prognostic
actors. Comparing the above nodal categories together in a
ox proportional hazards model, the only significant factor
n the multivariate model was the number of positive nodes
igure 1. Kaplan-Meier plot of UICC Stage, which did not satisfy
urvival accurately (P  .11).0-3 vs 4, hazard ratio, 3.6; 95% confidence interval,
and Cardiovascular Surgery ● Volume 131, Number 5 983
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G
TS.6-8.1; P  .002). The number of positive nodes was an
ndependent prognostic factor together with the hemoglobin
alue at diagnosis and the receipt of neoadjuvant or adju-
ant chemotherapy (Table 2).
iscussion
he purpose of this study was to examine whether the
xisting UICC staging system for MM, first proposed by the
nternational Mesothelioma Interest Group in 1995,1 is ap-
ropriate, taking into consideration what is known about the
ymphatic drainage of the pleura. MM is believed to arise on
he costal and diaphragmatic parietal pleura,4 which is re-
ected in T1a tumors being limited to the ipsilateral parietal
leura without involvement of the visceral pleura. The
ymph drainage of the costal parietal pleura flows initially
hrough intercostal lymphatic channels, anteriorly to inter-
al thoracic artery nodes or posteriorly to internal intercos-
al lymph nodes. Drainage can also be directly into axillary
r cervical lymph nodes. Diaphragmatic lymph can flow
nto mediastinal, internal thoracic, or abdominal nodes.10
isceral pleural lymph nodes might drain through interseg-
ental or interlobular septae to intraparenchymal nodes or
o hilar nodes directly through surface channels, hence to
ediastinal lymph nodes: this is equivalent to the lymph
rainage of the lung parenchyma itself. Hence lymph drain-
ge of parietal and visceral pleura can be considered to have
separate distributions, albeit with a proportion of the
arietal pleural drainage joining that of the visceral pleura in
he mediastinal lymph nodes.
Six different staging systems have, over the years, ad-
ressed the point of nodal staging in different ways. Three
ave assigned stage with and 3 have assigned stage without
NM criteria. With regard to nodal status, the systems
evised by Butchart and associates,11 Mattson,12 and Sug-
rbaker and colleagues13 all placed extrathoracic lymph
odes in stage III. The first TNM staging system14 placed N1
hilar) nodes in stage II and mediastinal (N2) nodes in stage III.
he initial UICC system15 did not mention ipsilateral N2
nternal thoracic artery nodes. Currently, the UICC identifies
psilateral internal thoracic artery nodes as N2, whereas dia-
ABLE 2. Significant prognostic variables identified in a
orward, stepwise, multivariate Cox proportional hazards
odel
ariable P value
Hazard
ratio
95% Confidence
interval
o neoadjuvant or
adjuvant chemotherapy
.001 3.4 1.6-7.0
emoglobin 14 g/dL .001 3.1 1.6-5.9
4 positive lymph nodes .009 3.0 1.3-6.9hragmatic nodes are not specifically considered. m
84 The Journal of Thoracic and Cardiovascular Surgery ● MayIn the light of the pattern of lymphatic drainage of the
arietal pleura, the concept of identifying all extrapleural
odes as N2 might need to be revised. Unfortunately, there
ere few patients with N1 disease alone or with isolated
ositive extrapleural nodes in our study, as well as in others
ublished since 1996.16 This denied us the statistical power
o test accurately the hypothesis that, for example, internal
horacic artery, diaphragmatic, and pericardial nodes de-
erve categorization as N1 nodes rather than N2 nodes. This
as raised in the article by Rusch1 presenting the IMIG
taging system in 1995. We noted that these nodal stations
epresented the site of skip metastases in 4 of the 14 cases.
Limitations of studies such as this include the uniformity
f systemic lymph node dissection. It is possible that despite
ur best efforts, bias existed in the extent of surgical lymph
ode sampling throughout the course of the study. Simi-
arly, there is possible bias in the uniformity of pathologic
nalysis (ie, the number of nodes retrieved from the resected
pecimen and embedded in paraffin or the number of section
evels through each tissue block). These 2 points are sug-
ested by a trend toward an increased number of nodes
oted in the pathology report with increasing case load,
lthough the trend was weak.
The question remains as to whether routine cervical
ediastinoscopy is justified in the selection of patients for
PP. We believe that the exclusion of patients with
ediastinoscopy-positive N2 disease is justified on the basis
f their relatively short postoperative survival. Thus every
ffort should be made to obtain biopsy specimens from as
any of the 7 lymph node stations accessible by means of
igure 2. Kaplan-Meier plot demonstrating the correlation be-
ween positive N2 status and poor survival (P  .02).ediastinoscopy as possible. However, it is accepted that a
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TSigh proportion of patients with N2 disease will not be
evealed by means of conventional mediastinoscopy (biopsy
pecimens from stations 1-4 and 7) because of the false-
egative rate of the investigation and the wide anatomic
istribution of N2 stations. However, we found that stations
, 4, or 7 were involved in 27 (77%) of the 35 N2-positive
ases, although the negative predictive value for station 7, in
articular, was not high. There are no data regarding ex-
ended mediastinoscopy17 in MM, which might not be pos-
ible in many cases because of pleural thickening.
With a number of groups, including our unit, using
ediastinal staging to exclude patients with N2 disease
rom radical surgery protocols,7,18-20 it might be more diffi-
ult in the future to obtain the data required for prospective
tudies and the sufficient number of patients with N2 disease to
larify the prognostic hypotheses raised by this study.
Skip metastases are a common feature of MM after
adical surgical intervention. We were unable to demon-
trate differences in survival between skip N2 and the other
odal categories. Larger studies are required to examine
hether skip metastases and the first-level nodes draining
he parietal pleura confer a different prognosis to mediasti-
al N2 nodes.
Rusch1 considered the number of nodes involved and
ound, as in this study, a significant survival difference
etween those with 0 to 3 and those with greater than or
qual to 4 positive nodes. We were not able to stratify
urvival by the absolute number of involved nodes in those
atients with malignant lymphadenopathy (P  .11). How-
ver, the proportion of nodes analyzed does seem to be a
igure 3. Kaplan-Meier plot to show the negative impact on
urvival of a proportion of positive N2 nodes greater than the
edian (P  .04).etter indicator of prognosis, both with respect to N1 and
The Journal of Thoracic2 nodes separately and combined. To determine whether
ephalad nodes in the mediastinal chain (stations 2, 4, and
) bore a worse prognosis, those with these stations positive
ere compared with those with the involved nodes confined
lsewhere. The latter group represent those with the only
ositive nodes in locations not accessible to mediastinos-
opy. There was no survival difference.
In conclusion, because we have not seen the differential
rognosis between the N1 and N2 stages, we believe that
evision of the UICC staging system needs to be considered.
ne cannot transfer the anatomic conclusions of NSCLC to
M because of intrinsic differences in the lymphatic drain-
ge patterns. Furthermore, although mediastinoscopy can-
ot assess all N2 stations, it is a useful tool for EPP selection
nd should be performed routinely.
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iscussion
r Raja M. Flores (New York, New York). The incidence of
esothelioma in Europe is increasing, with a projected 250,000
ew cases expected over the next 30 years. Therefore it is only
tting that we collaborate with our European colleagues to try and
mprove treatment. Edwards and his group from the United
ingdom present data on 92 patients undergoing EPP. This study
s a useful addition to the literature because it provides confirma-
ory data concerning the effect of lymph node involvement on
urvival. Significant positive findings in this study include the
ollowing: positive N2 nodes portend a worse prognosis than
egative N2 nodes, patients with 4 or more positive nodes do
orse than patients with less than 4 nodes, and patients with a
reater proportion of positive nodes also do worse. These findings
re in accord with the 183 patients from Sugarbaker in Boston and
he data on 231 patients from Rusch from our own institution in
ew York. In contrast, another large European study by Aziz from
cotland on 111 surgically resected patients did not demonstrate a
tatistically significant difference in survival when patients were
tratified on the basis of nodal status. An important negative
nding of this study is that there is no difference in survival among
atients with positive N2 nodes accessible by means of mediasti-
oscopy (ie, level 4 and level 7) when compared with N2 nodes
naccessible to mediastinoscopy (ie, levels 8, 9, and internal tho-
acic artery). However, the numbers are small. Inconclusive areas
f this study include the influence of N1 nodes, which were only
resent in 9 cases, and the influence of N2 skip nodes, which were
resent in only 14 cases.
I disagree with the presenter’s conclusion that all patients with
ositive N2 nodes should be denied surgical resection at this point
n time. No single prognostic factor should be taken by itself. The
xtent of primary tumor, histology, the role of newer and more
ffective chemotherapeutic regimens (eg, gemcitabine and pem-
trexed), and the role of high-dose hemithoracic radiation must be
onsidered before denying surgical intervention to appropriate
atients.
The numbers are much too small and not without some con-
radiction to draw any firm conclusions. Rather than deny these
atients surgical intervention, patients with positive nodes, as well
s all patients with mesothelioma, should be treated in a clinical
rial setting. t
86 The Journal of Thoracic and Cardiovascular Surgery ● MayThe most significant predictor of survival is histology. As a
atter of fact, that is probably the only thing that everyone in this
oom would agree on. Although you excluded patients with sar-
omatoid disease from the beginning on the basis of open lung
iopsy, Bueno and the group from Boston reported on 302 pa-
ients. Forty-four percent of patients initially thought to have
pithelioid disease on the basis of histology were found to not have
pithelioid disease on the basis of histology at surgical resection.
herefore it is unlikely that all 92 patients who were initially given
iagnoses of epithelioid disease actually have epithelioid disease at
nal resection. I did not see a stratification of survival by final
istologic subtype, nor did I see a multivariate analysis performed
ncluding histology and nodal status. Was such an analysis per-
ormed? If not, the addition of these data would greatly strengthen
he content of this already important contribution.
Dr Edwards. I agree that we do need to perform a multivariate
nalysis, and that will be done. There were 17 of the 92 patients
ho had mixed or biphasic histology. I do not have the data on me
o confirm how many of those were previously identified as having
pithelioid disease on the basis of biopsy, but those data can be
btained.
Dr Flores. My second question is with regard to multimodality
reatment. It appears as if the majority of your patients underwent
urgical intervention alone. Later in the study, 20 patients under-
ent induction therapy, and 6 underwent adjuvant therapy. Why
id you change your treatment? Also, did any patients receive
ostoperative radiation? If so, was this routine, and what was the
osage given?
Dr Edwards. The intention was to offer surgical intervention as
art of the multimodality program, and this is a multi-institutional
tudy, although operations were performed by a single surgeon in
single center. Oncologic treatment was administered in 28 cen-
ers around the country, over which we had no jurisdiction. Six
atients had trimodal therapy, and 9 had further radical radiother-
py in a dose of between 20 and 54 Gy.
Dr Flores. My next question is a difficult one regarding the role
f mediastinoscopy. Of the 30 patients who underwent mediasti-
oscopy, 10 had false-negative results in the level 4 and level 7
reas. In addition, 8 patients had positive lymph nodes inaccessible
o mediastinoscopy, which adds up to a total of 18. Therefore 18
f 35 patients with positive N2 nodes would be identified by means
f mediastinoscopy. The chances of identifying those patients are
ust as good as if flipping a coin. Therefore taking this into
ccount, how should patients with positive N2 nodes be managed
y means of mediastinoscopy or not, and how does this change
our management?
Dr Edwards. I agree that although mediastinoscopy cannot
ssess all N2 stations that we found—and I draw your attention to
hose 8 of the 35 patients who had N2 disease purely in stations
ther than 2, 4, and 7—we do believe that it is a useful exclusion
ool for EPP on the basis of our survival data. We do not believe
hat we should offer EPP in those who we know have N2 disease
n the basis of a median survival of 12 months. It does not justify
he mortality and morbidity.
Dr Flores. And then one quarter of your 92 patients had EPP
erformed through a median sternotomy. The picture shows a
ignificant amount of diaphragm remaining. What are the advan-
ages to sternotomy in performing this procedure, and in cases in
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TShich complete diaphragmatic resection is necessary, have you
ad difficulty in reconstruction and placing the patch at a low
nough level to facilitate postoperative radiotherapy?
Dr Edwards. As presented at the Society of Thoracic Surgeons
eeting in Tampa earlier by my colleague, Dr Martin-Ucar, we
ow use this incision routinely for right EPP because of benefits in
perative time, postoperative pain, and hospital stay. The picture I
howed you was a patient in whom the tumor could be mobilized
ithout resecting the entire diaphragmatic muscle, and I agree that
t has been difficult to reconstruct, but we have been able to
econstruct at the original level in all patients.
Dr Flores. This is much needed confirmatory data in the
iterature.
Dr Edwards. Which is out with this talk.
Dr W. Roy Smythe (Temple, Tex). I enjoyed your presentation.
Knowing what we know about the difficulty in discerning the
xtramediastinal lymph nodes preoperatively by means of positron
mission tomographic scanning, because often the pleural tumor is
djacent to the mediastinal nodes, it is difficult to tell what is a
umor and what is a node. Especially with a bulky tumor, you can
ften not discern a positive internal thoracic, a paraesophageal, or
n inferior pulmonary ligament node from the tumor itself.
Dr Edwards. Absolutely.
Dr Smythe. Therefore I want you to explain to me how we are
o evaluate those nodal stations preoperatively and exclude those
atients who exhibit evidence of nodal involvement.
Dr Edwards. We do not have any experience with positron
mission tomography in this series, and I think it will remain very
ifficult to evaluate those nodes that you mentioned.
Dr David J. Sugarbaker (Boston, Mass). I have a couple of
uestions.
Back in 1994, initial series showed that positive nodes of any
ind had a statistical reduction in overall survival with EPP fol-
owed by chemotherapy and radiation. That was then updated, and
hat fell out was that the N1 nodes and N0 nodes, similar to what
think you were alluding to, although I am hoping you can help me
ut, were similar, but we used the term extrapleural nodes as being
nes that had a real negative effect on long-term survival. t
The Journal of ThoracicNow on the one hand you used the term N2 disease, and on
he other hand you used the term extrapleural disease. There is
significant amount of literature regarding the fact that ex-
rapleural disease in nodes has a negative prognostic overall effect
n survival. Therefore are you calling it N2? Are you calling it
xtrapleural? What is your terminology, because I am really losing
ou.
Dr Edwards. The definition of N2 is that used by the UICC
ystem. That is effectively what we have used.
Dr Sugarbaker. But you also used the term extrapleural nodes.
Dr Edwards. Well, I use extrapleural, and I do use that
nterchangeably. By extrapleural I do mean N2 nodes because the
2 nodes are extrapleural by definition.
Dr Raphael Bueno (Boston, Mass). I thought you said that
our results did not correlate in terms of survival with the UICC
taging. Maybe I am wrong, but I thought I heard that. Did you try
ny other staging systems?
Dr Edwards. We have not in this study. I have done previ-
usly, but not with these numbers, no.
Dr Sugarbaker. Specifically, have you tried the Brigham
taging system?
Dr Edwards. I just might do that.
Dr Sugarbaker. Because it is not unusual to see those lines
ike spaghetti with the staging system that you used. I will just
hrow that out there.
Dr Joseph S. Friedberg (Philadelphia, Pa). I am also inter-
sted in the median sternotomy approach. For a tumor that likes to
eed incisions, it seems like the marrow of the exposed sternum
ight be a problem. Have you seen any recurrences in that area?
Dr Edwards. We have not seen recurrence in the 23 patients.
Dr Friedberg. Do you include that in your postoperative
adiation field?
Dr Edwards. Well, as I say, our uptake of adjuvant therapy has
een low. I am not sure whether any of those patients have
eceived adjuvant therapy. I do not think so.
Dr Sugarbaker. How about your subcarinal dissection through
sternotomy, have you found that at all difficult?
Dr Edwards. We have managed to clear out down the con-
ralateral bronchus each time.
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